Proposals for a Phenotypic Classification of B-Chronic Lymphocytic Leukemia, Relationship with Prognostic Factors.

abstract：:Mastocytosis comprises a heterogeneous group of disorders characterized by proliferation and accumulation of mast cells in 1 or more organ systems. Mast cell leukemia (MCL) is an extremely rare subtype of mastocytosis in which a leukemic spread of mast cells and a rapid progression of disease is seen. In typical cases...

journal_title：Leukemia & lymphoma

authors： Noack F,Sotlar K,Notter M,Thiel E,Valent P,Horny HP

更新日期：2004-11-01 00:00:00

abstract：:The tyrosine kinase inhibitors (TKIs), nilotinib, ponatinib, and dasatinib (but not bosutinib or imatinib), are associated with vascular adverse events (VAEs) in chronic myeloid leukemia (CML). Though the mechanism is inadequately understood, an effect on vascular cells has been suggested. We investigated the effect o...

journal_title：Leukemia & lymphoma

authors： Gover-Proaktor A,Granot G,Pasmanik-Chor M,Pasvolsky O,Shapira S,Raz O,Raanani P,Leader A

更新日期：2019-01-01 00:00:00

abstract：:We describe here a rare case of malignant lymphoma followed by plasmacytoma in Hashimoto's thyroiditis. The patient developed malignant lymphoma (small, non-cleaved cell, and non Burkitt's type by Working Formulation classification), and remained in remission for 2 years after receiving combination chemotherapy, and t...

journal_title：Leukemia & lymphoma

authors： Hasegawa Y,Itoh T,Tamagawa Y,Komeno T,Kojima H,Ninomiya H,Yatabe Y,Mori N,Nagasawa T

更新日期：1999-11-01 00:00:00

abstract：:Primary breast lymphoma (PBL) is a rare form of localized extranodal lymphoma. Few reports are available in the literature concerning its treatment and outcome. Of the 34 cases of PBL seen at our institution over a 25-year period, 20 consecutive cases were treated with CHOP or CHOP-like chemotherapy regimen and had ad...

journal_title：Leukemia & lymphoma

authors： Gholam D,Bibeau F,El Weshi A,Bosq J,Ribrag V

更新日期：2003-07-01 00:00:00

abstract：:The objective of this work was to determine the safety and efficacy of gemtuzumab ozogamicin in patients with poor prognosis acute myeloid leukemia (AML). Patients with the following diagnoses/characteristics were treated with 1-3 infusions of gemtuzumab ozogamicin at a dose of 9 mg/m2: (1) relapse of AML < or = 6 mon...

journal_title：Leukemia & lymphoma

authors： Roboz GJ,Knovich MA,Bayer RL,Schuster MW,Seiter K,Powell BL,Woodruff RD,Silver RT,Frankel AE,Feldman EJ

更新日期：2002-10-01 00:00:00

abstract：:Adolescents and adults with acute lymphoblastic leukemia/lymphoma (ALL) have better outcomes when treated using pediatric protocols compared with treatment using adult protocols. We reviewed the progress and outcomes of 40 adolescents and adults up to 45 years of age, from three Australian centers, treated on the inte...

journal_title：Leukemia & lymphoma

authors： Hocking J,Schwarer AP,Gasiorowski R,Patil S,Avery S,Gibson J,Iland H,Ho PJ,Joshua D,Muirhead J,Lai H,Irving I

更新日期：2014-12-01 00:00:00

abstract：:NK/T-cell lymphoma is difficult to diagnose because there is no characteristic cytology to help the diagnosis in tissue sections, particularly when there is polymorphic cellular infiltration in the early stage of the disease. However, the nasal type of extranodal NK/T-cell lymphoma has a characteristic histologic patt...

journal_title：Leukemia & lymphoma

authors： Jia H,Sun T

更新日期：2004-07-01 00:00:00

abstract：:Differential gene expression analysis by suppression subtractive hybridization with correlation to the metabolic pathways involved in chronic myeloid leukemia (CML) may provide a new insight into the pathogenesis of CML. Among the overexpressed genes found in CML at diagnosis are SEPT5, RUNX1, MIER1, KPNA6 and FLT3, w...

journal_title：Leukemia & lymphoma

authors： Mascarenhas Cdo C,Ferreira da Cunha A,Brugnerotto AF,Gambero S,de Almeida MH,Carazzolle MF,Pagnano KB,Traina F,Costa FF,de Souza CA

更新日期：2014-08-01 00:00:00

abstract：:Lymphoblastic lymphoma (LBL) is a neoplasm of precursor B- or T-lymphocytes, and primary skin involvement is uncommon. The aim of the study was to review all reported primary cutaneous (PC)-LBLs and to examine three new cases to better characterize this neoplasm. Two of our patients showed a pre-B phenotype (PC-B-LBL)...

journal_title：Leukemia & lymphoma

authors： Vezzoli P,Novara F,Fanoni D,Gambini D,Balice Y,Venegoni L,Paulli M,Crosti C,Berti E

更新日期：2012-10-01 00:00:00

abstract：:Nuclear factor-kappaB (NF-kappaB) is a transcriptional factor that was originally discovered in the nucleus of B cells that bind to the kappa light chain of the immunoglobulins. Research during 15 years, however, has revealed that NF-kappaB is present in its inactive state in the cytoplasm of almost every cell type. W...

journal_title：Leukemia & lymphoma

authors： Younes A,Garg A,Aggarwal BB

更新日期：2003-06-01 00:00:00

abstract：:Conventional G-banding cytogenetics (CC) detects chromosome 17 (chr17) abnormalities in 2% of patients with de novo myelodysplastic syndromes (MDS). We used CC and fluorescence in situ hybridization (FISH) (LSI p53/17p13.1) to assess deletion of 17p in 531 patients with de novo MDS from the Spanish Group of Hematologi...

journal_title：Leukemia & lymphoma

authors： Sánchez-Castro J,Marco-Betés V,Gómez-Arbonés X,García-Cerecedo T,López R,Talavera E,Fernández-Ruiz S,Ademà V,Marugan I,Luño E,Sanzo C,Vallespí T,Arenillas L,Marco Buades J,Batlle A,Buño I,Martín Ramos ML,Blázquez Rios B

更新日期：2015-01-01 00:00:00

abstract：:Adhesion molecules such as CD2 and its ligand CD58 (LFA-3), as well as CD11a/18 (LFA-1) and CD54 (ICAM-1) regulate not only cell to cell attachment but also participate in lymphocyte activation, recirculation, and effector function including cytolytic activity towards tumor cells. We have investigated the role of CD2/...

journal_title：Leukemia & lymphoma

authors： Schirren CA,Völpel H,Hoffmann JC,Henning SW,Qiao L,Autschbach F,Dengler TJ,Döhner H,Meuer SC

更新日期：1993-05-01 00:00:00

abstract：:The approval of venetoclax, a 'BH3-mimetic' antagonist of the BCL-2 anti-apoptotic protein, for chronic lymphocytic leukemia represents a major milestone in translational apoptosis research. Venetoclax has already received 'breakthrough' designation for acute myeloid leukemia, and is being studied in many other tumor ...

journal_title：Leukemia & lymphoma

authors： Bose P,Gandhi V,Konopleva M

更新日期：2017-09-01 00:00:00

abstract：:The occurrence of unexplained peripheral blood cytopenia, particularly neutropenia, has been recently reported after rituximab. Its prevalence may be underestimated since it may occur late after treatment. This study analysed all cases of unexplained delayed-onset peripheral blood cytopenia of WHO grade II - IV occurr...

journal_title：Leukemia & lymphoma

authors： Cattaneo C,Spedini P,Casari S,Re A,Tucci A,Borlenghi E,Ungari M,Ruggeri G,Rossi G

更新日期：2006-06-01 00:00:00

abstract：:The combination of mitoxantrone (MIT), etoposide (ETP), and cytarabine (Ara-C) (MEC) is a frequently used salvage therapy for acute leukemia, but has been associated with severe myelosuppression. Therefore, we investigated the miniMEC regimen with reduced doses of AraC and MIT. Thirteen ALL and 44 AML patients, all re...

journal_title：Leukemia & lymphoma

authors： Yamamoto C,Ito S,Mashima K,Umino K,Minakata D,Yamasaki R,Kawasaki Y,Sugimoto M,Nakano H,Ashizawa M,Okazuka K,Hatano K,Sato K,Oh I,Fujiwara S,Ohmine K,Suzuki T,Muroi K,Kanda Y

更新日期：2016-11-01 00:00:00

abstract：:Tumor necrosis factor alpha (TNF-alpha) and lymphotoxin alpha (LT-alpha) have been shown to play an important role in the pathogenesis of limphoproliferative disease. Both cytokines regulate cell-survival and cell-death in leukemic cells. TNF-alpha and LT-alpha are highly produced in chronic lymphotic leukemia (CLL) a...

journal_title：Leukemia & lymphoma

authors： Jevtovic-Stoimenov T,Kocic G,Pavlovic D,Macukanovic-Golubovic L,Marjanovic G,Djordjevic V,Tosić N,Pavlović S

更新日期：2008-11-01 00:00:00

abstract：:2-Chlorodeoxyadenosine (2-CdA) is associated with prolonged suppression of CD4 lymphocytes. Cases of tuberculosis or mycobacterium avium intracellulare complex (MAC) infection complicating 2-CdA administration have not been reported despite the low CD4 counts. We report a patient with Hairy Cell Leukaemia (HCL) who de...

journal_title：Leukemia & lymphoma

authors： Broady R,Roberts S,Hawkins T

更新日期：2000-02-01 00:00:00

abstract：:We investigated the possibility of immunotherapy for multiple myeloma (MM) using myeloma-specific cytotoxic T lymphocytes (CTLs) that were stimulated in vitro by dendritic cells (DCs) pulsing with purified and optimized myeloma lysates. CD14(+) cells were cultured in the presence of GM-CSF and IL-4. On day 6, the imma...

journal_title：Leukemia & lymphoma

authors： Lee JJ,Choi BH,Kang HK,Park MS,Park JS,Kim SK,Pham TN,Cho D,Nam JH,Kim YJ,Rhee JH,Yang DH,Kim YK,Kim HJ,Chung IJ

更新日期：2007-10-01 00:00:00

abstract：:Chronic myeloid leukemia (CML) is rare among children and adolescents. The early molecular response (EMR) is an important prognostic significance for adult CML patients. This study explored the impact of EMR on the prognosis in 40 children and adolescents with CML-CP treated with imatinib (IM). Our results showed that...

journal_title：Leukemia & lymphoma

authors： Shao H,Zeng Z,Cen J,Zhang J,Bai S,Wu C,Gong Y,Wang Y,Qiu H,Chen S,Pan J

更新日期：2018-09-01 00:00:00

abstract：:In the present study we assess the antitumor effect and circulating stem cells (CSC) mobilizing capacity of high-dose cyclophosphamide (5 to 7 gr/m2, HDCY). This treatment was given to 21 patients with various hematologic malignancies (8 NHL, 5 MM, 4 HD, 3 CML) excluding 1 with neuroblastoma. All were eligible for lat...

journal_title：Leukemia & lymphoma

authors： Indovina A,Majolino I,Scimè R,Vasta S,Gentile S,Liberti G,Santoro A,Pampinella M,Caronia F

更新日期：1994-06-01 00:00:00

abstract：:High dose cytosine arabinoside (HDARAC) was administered to eleven patients in the blastic phase of Philadelphia (Ph) chromosome positive chronic myelogenous leukemia (CML). Four patients presented in blastic phase and in seven patients blastic transformation had evolved from a previous chronic phase. All patients had...

journal_title：Leukemia & lymphoma

authors： Kempin S,Arlin Z,Berman E,Gee T,Mertelsmann R,Andreeff M,Kolitz J,Jhanwar S,Myers J,Clarkson B

更新日期：1991-01-01 00:00:00

abstract：:The objective was to evaluate the feasibility and efficacy of a short-term, multi-agent and dose intensive regimen in AIDS patients with Burkitt or Burkitt-like lymphoma (BL/BLL) and to compare its efficacy with that of a conventional regimen. This was a retrospective, multi-center cohort study of all HIV-1-infected p...

journal_title：Leukemia & lymphoma

authors： Hoffmann C,Wolf E,Wyen C,Fätkenheuer G,Van Lunzen J,Stellbrink HJ,Stoehr A,Plettenberg A,Jaeger H,Noppeney R,Hentrich M,Goekbuget N,Hoelzer D,Horst HA

更新日期：2006-09-01 00:00:00

abstract：:Several studies have been conducted to examine the association between IKZF1 rs4132601 polymorphism and acute lymphoblastic leukemia (ALL) risk. However, the conclusions remain controversial. We therefore performed a meta-analysis. PubMed, Embase, Web of Science, Weipu and Chinese Biomedical Literature (CBM) databases...

journal_title：Leukemia & lymphoma

authors： Li S,Ren L,Fan L,Wang G

更新日期：2015-04-01 00:00:00

abstract：:131 patients with Philadelphia (Ph') chromosome positive chronic myelogenous leukemia (CML) were treated with interferon (IFN) alpha or a combination of IFN alpha and IFN gamma. In study, 1, 13 not pretreated and 41 pretreated patients, 48 in chronic phase disease, 6 in accelerated phase, received 4 x 10(6) U/m2 IFN a...

journal_title：Leukemia & lymphoma

authors： Niederle N,Kloke O,Wandl UB,Becher R,Moritz T,Opalka B

更新日期：1993-01-01 00:00:00

abstract：:Recent advances in genomics are revealing new molecular targets for vaccination strategies in cancer, and unraveling the immune pathways that must be activated. Initially, work focused on idiotypic antigen expressed by the clonal immunoglobulin (Ig) of B-cell tumors. This involved assembling the encoding V(H) and V(L)...

journal_title：Leukemia & lymphoma

authors： Stevenson FK,King A,Ottensmeier CH

更新日期：2003-01-01 00:00:00

abstract：:Peripheral lymphopenia is a well-known negative prognostic marker in classical Hodgkin lymphoma (cHL). We characterized the peripheral B-cell compartment in a prospective cohort of 83 pediatric cHL patients. We observed significantly low total B-cell counts (<100 cells/µl) in 31 of 83 patients (37%). More specifically...

journal_title：Leukemia & lymphoma

authors： Hamdi L,Creidy R,Boudjemaa S,Hendel-Chavez H,Hugues P,Taoufik Y,Leblanc T,Coulomb A,Krzysiek R,Landman-Parker J,Besson C

更新日期：2020-10-23 00:00:00

abstract：:Aggressive B-cell non-Hodgkin lymphoma (aNHL) accounts for ∼50% of all NHL cases. The only potentially curative, broadly available treatment for patients with relapse, failing frontline treatment, is high-dose therapy followed by autologous stem cell transplantation (ASCT); patients ineligible for/who have failed ASCT...

journal_title：Leukemia & lymphoma

authors： Salles GA,Pettengell R,Cordoba R,Długosz-Danecka M,Jurczak W,Tilly H

更新日期：2019-07-01 00:00:00

abstract：:The development of techniques permitting in vitro growth of human megakaryocytes progenitors and more recently identification of the proto oncogene c-mpl (Mpl-R) and its ligand (Mpl-L) have created new opportunities for studying pathophysiology of E.T. Plasma or serum of E.T. patients was unable to overestimulate MK c...

journal_title：Leukemia & lymphoma

authors： Yan L,Elkassar N,Gardin C,Briere J

更新日期：1996-09-01 00:00:00

abstract：:The ubiquitin-proteasome-dependent proteolytic system has been reported to regulate apoptotic cell death in many experimental cell models. We recently found that B-CLL (chronic lymphocytic leukemia) lymphocytes are hypersensitive to apoptotic death activation through specific inhibition of proteasome function by lacta...

journal_title：Leukemia & lymphoma

authors： Masdehors P,Merle-Béral H,Magdelénat H,Delic J

更新日期：2000-08-01 00:00:00

abstract：:The number of circulating plasma cells (CPC) was determined on mononuclear cell preparations after Giemsa (morphology) and light chain staining (immunocytochemistry). Both methods gave reproducible and identical results when CPC were 1% or more. Using this limit, no CPC were observed in MGUS (0/11) and primary amyloid...

journal_title：Leukemia & lymphoma

authors： Zandecki M,Facon T,Preudhomme C,Canis F,Izydorczyk V,Lovi V,Hammad M,Bauters F,Cosson A

更新日期：1994-08-01 00:00:00